Last checked at 19 Sep 2013 07:00
For immediate release | 19 September 2013 |
Oxford BioMedica plc Director's Share Purchase
Oxford, UK - 19 September 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 18 September that one of its Directors has acquired ordinary shares of 1p each ("Ordinary Shares") as follows:
|
|
|
| Interest after purchase | |
Director / PDMR | Title | Price per share (p) | Number of Ordinary Shares acquired on 18 September 2013 | Number of Ordinary Shares | % of total issued share capital |
Andrew Heath | Non-Executive Director | 2.58 | 100,000 | 600,000 | 0.042% |
The issued share capital of the Company is 1,416,149,005 1p ordinary shares.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: Lara Mott, Head of Investor Relations and Corporate Communications |
Tel: +44 (0)1865 783 000 |
Nomura Code Securities Limited: Juliet Thompson/Chris Golden |
Tel: +44 (0)20 7776 1200 |
Media/Financial Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications |
Tel: +44 (0)20 7920 2354
|
Notes to editors
1. About Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.ukand www.oxbsolutions.co.uk.